By Dave Sebastian

Becton, Dickinson and Co. (BDX) on Thursday lowered its fiscal-year 2020 outlook as the company said it is continuing to work the Federal Drug Administration on its remediation plan for the Alaris System and is anticipating loss of sales of the Alaris infusion system.

Shares fell 3.8% in premarket trading.

The medical-technology company now sees full-year revenue to increase 1.5% to 2.5%, or 2.5% to 3.5% on a currency-neutral basis. It previously expected revenue to increase 4% to 4.5%, or 5% to 5.5% on a currency-neutral basis.

The company expects adjusted earnings of $11.90 a share to $12.10 a share, reflecting a growth of about 4% to 5.5% on a currency-neutral basis over fiscal 2019 and a 2% to 3.5% growth including the effects of foreign currency. It previously expected adjusted earnings of $12.50 a share to $12.65 a share.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

February 06, 2020 07:06 ET (12:06 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Becton Dickinson Charts.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Becton Dickinson Charts.